Raleigh, NC, December 14, 2023—Veranex, provider of the first purpose-built, global service platform for the medtech industry, today announced that it has acquired T3 Labs, a highly reputable preclinical laboratory located in Atlanta, Georgia. This acquisition solidifies Veranex’s commitment to expanding its preclinical footprint in North America, deepening its therapeutic expertise, and providing customers with enhanced flexibility.
“The addition of T3 Labs to the Veranex family allows us to further realize our mission of unifying the entire medtech development process, from concept to commercialization,” said Pat Donnelly, CEO of Veranex. “The growth of the preclinical market, increasing regulatory requirements, and the need for efficient collaboration between customers and product development make T3 Labs a strategic fit for Veranex and an incredible asset for our customers.”
T3 Labs is a leader in preclinical testing services in the United States and boasts a 33,000-square-foot facility with innovative equipment, training facilities, and state-of-the-art operating rooms dedicated to research in 12 therapeutic areas. As an anchor in Science Square, a growing life sciences hub in Atlanta, Georgia, T3 Labs shares strategic community relationships with the Centers for Disease Control and Prevention (CDC), Emory University, Georgia Tech, and others. The staff at T3 Labs brings deep preclinical medical device expertise, having had more than 60 products approved by the FDA over the past ten years. T3 Labs complements Veranex PCS France, which boasts a 25-year history of providing world-class preclinical services. T3 Labs and Veranex PCS France provide customers with world-class, turn-key, comprehensive preclinical service offerings.
T3 Labs is led by Sherry Farrugia, an entrepreneur and executive leader with over 30 years of leadership experience in the healthcare and medical device industry, and Jeff White, DVM, a biomedical operations executive with extensive experience in medtech innovation operations.
“Joining the Veranex family enables T3 Labs to better serve the greater MedTech and Science Square community, ” said Sherry Farrugia. “By combining our expertise and offerings with Veranex’s existing preclinical services, we are excited about the impact we can make for our customers and the industry at large.”
Dr. Jeff White adds, “Veranex holds very high standards for the services it provides to its customers, a value that the company and T3 Labs have in common. Together, T3 Labs and Veranex can deliver more integrated, valuable, customized services to the medtech community. We look forward to our future innovations.”
Additional details about Veranex’s expanded preclinical services can be found here. To learn more about Veranex and its revolutionary approach to end-to-end service offerings for medical technology, visit veranex.com or follow the company on LinkedIn.
Veranex is the provider of the first purpose-built, global service platform for the medtech industry. From concept to commercialization, Veranex enables companies of all sizes to benefit from accelerated speed to market, controlled development costs, mitigation of development risks, and market viability assessment. The company’s holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail. This makes Veranex a trusted partner to help companies quickly and efficiently deliver innovative products while ensuring the highest level of quality and compliance. Veranex is backed by Summit Partners, Accelmed, and Lauxera. For more information, visit Veranex.com and follow Veranex on LinkedIn.